PMID- 28452054
OWN - NLM
STAT- MEDLINE
DCOM- 20171004
LR  - 20200306
IS  - 1097-0142 (Electronic)
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 123
IP  - 17
DP  - 2017 Sep 1
TI  - Comparing outcomes of matched related donor and matched unrelated donor 
      hematopoietic cell transplants in adults with B-Cell acute lymphoblastic 
      leukemia.
PG  - 3346-3355
LID - 10.1002/cncr.30737 [doi]
AB  - BACKGROUND: Allogeneic hematopoietic cell transplantation (HCT) using human 
      leukocyte antigen (HLA)-matched related donors (RDs) and allogeneic HCT using 
      HLA-matched unrelated donors (URDs) produce similar outcomes for patients with 
      acute myelogenous leukemia, whereas the donor source has been reported to be a 
      predictor of outcomes in myelodysplastic syndrome. METHODS: Post-HCT outcomes for 
      1458 acute lymphoblastic leukemia patients from 2000 to 2011 were analyzed, and 
      RD and URD transplants were compared. RESULTS: The median age was 37 years 
      (range, 18-69 years). In the multivariate analysis, HLA 8/8 allele-matched URD 
      recipients had similar transplant-related mortality (TRM) and all-cause mortality 
      in comparison with RD recipients (hazard ratios [HRs], 1.16 [95% confidence 
      interval (CI), 0.91-1.48] and 1.01 [95% CI, 0.85-1.19], respectively); 7/8 URD 
      recipients had a greater risk of TRM and all-cause mortality in comparison with 
      RD recipients (HRs, 1.92 [95% CI, 1.47-2.52] and 1.29 [95% CI, 1.05-1.58], 
      respectively). The risk of TRM and all-cause mortality was also greater for 7/8 
      URD recipients versus 8/8 URD recipients. Compared with RD recipients, both 8/8 
      and 7/8 URD recipients had a lower risk of relapse (HRs, 0.77 [95% CI, 0.62-0.97] 
      and 0.75 [95% CI, 0.56-1.00], respectively). Both 8/8 and 7/8 URD recipients had 
      a greater risk of acute graft-versus-host disease (GVHD; HRs, 2.18 [95% CI, 
      1.76-2.70] and 2.65 [95% CI, 2.06-3.42], respectively) and chronic GVHD (HRs, 
      1.28 [95% CI, 1.06-1.55] and 1.46 [95% CI, 1.14-1.88], respectively) in 
      comparison with RD recipients. CONCLUSIONS: In the absence of RD transplantation, 
      8/8 URD transplantation is a viable alternative with similar survival outcomes, 
      whereas 7/8 URD transplantation is associated with poorer overall survival. 
      Cancer 2017;123:3346-55. (c) 2017 American Cancer Society.
CI  - (c) 2017 American Cancer Society.
FAU - Segal, Eric
AU  - Segal E
AUID- ORCID: 0000-0003-1873-171X
AD  - Medical College of Wisconsin Affiliated Hospitals, Milwaukee, Wisconsin.
FAU - Martens, Michael
AU  - Martens M
AD  - Division of Biostatistics, Medical College of Wisconsin, Milwaukee, Wisconsin.
FAU - Wang, Hai-Lin
AU  - Wang HL
AD  - Center for International Blood and Marrow Transplant Research, Medical College of 
      Wisconsin, Milwaukee, Wisconsin.
FAU - Brazauskas, Ruta
AU  - Brazauskas R
AD  - Division of Biostatistics, Medical College of Wisconsin, Milwaukee, Wisconsin.
FAU - Weisdorf, Daniel
AU  - Weisdorf D
AD  - Division of Hematology, Oncology, and Transplantation, University of Minnesota, 
      Minneapolis, Minnesota.
FAU - Sandmaier, Brenda M
AU  - Sandmaier BM
AD  - Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, 
      Washington.
FAU - Khoury, H Jean
AU  - Khoury HJ
AUID- ORCID: 0000-0002-8434-3988
AD  - Department of Hematology and Medical Oncology, Emory University, Atlanta, 
      Georgia.
FAU - de Lima, Marcos
AU  - de Lima M
AD  - University Hospitals Case Medical Center, Cleveland, Ohio.
FAU - Saber, Wael
AU  - Saber W
AD  - Center for International Blood and Marrow Transplant Research, Medical College of 
      Wisconsin, Milwaukee, Wisconsin.
LA  - eng
GR  - U10 HL069294/HL/NHLBI NIH HHS/United States
GR  - U24 CA076518/CA/NCI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
DEP - 20170427
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - *Cause of Death
MH  - Cohort Studies
MH  - Female
MH  - Graft Rejection
MH  - Graft Survival
MH  - HLA Antigens/immunology
MH  - Hematopoietic Stem Cell Transplantation/adverse effects/*methods
MH  - Histocompatibility Testing/*methods
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Precursor Cell Lymphoblastic Leukemia-Lymphoma/*diagnosis/mortality/*surgery
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Retrospective Studies
MH  - Risk Assessment
MH  - Severity of Illness Index
MH  - Sex Factors
MH  - Survival Analysis
MH  - Transplantation, Homologous/adverse effects/methods
MH  - Treatment Outcome
MH  - Unrelated Donors/statistics & numerical data
MH  - Young Adult
PMC - PMC5568918
MID - NIHMS865044
OTO - NOTNLM
OT  - acute lymphoblastic leukemia (ALL)
OT  - allogeneic transplantation
OT  - human leukocyte antigen (HLA) match
OT  - related donors
OT  - stem cell transplantation
OT  - unrelated donors
COIS- Conflict of interest disclosure: The authors declare no competing financial 
      interests.
EDAT- 2017/04/30 06:00
MHDA- 2017/10/05 06:00
PMCR- 2018/09/01
CRDT- 2017/04/29 06:00
PHST- 2016/12/12 00:00 [received]
PHST- 2017/03/06 00:00 [revised]
PHST- 2017/03/21 00:00 [accepted]
PHST- 2017/04/30 06:00 [pubmed]
PHST- 2017/10/05 06:00 [medline]
PHST- 2017/04/29 06:00 [entrez]
PHST- 2018/09/01 00:00 [pmc-release]
AID - 10.1002/cncr.30737 [doi]
PST - ppublish
SO  - Cancer. 2017 Sep 1;123(17):3346-3355. doi: 10.1002/cncr.30737. Epub 2017 Apr 27.